News
Article
PTSM: Pharmaceutical Technology Sourcing and Management
PTSM: Pharmaceutical Technology Sourcing and Management
EMA Releases API Bioequivalence Studies Guidance
Author(s):
The agency has released guidance on bioequivalence studies for asenapine, prasugrel, sitagliptin, and zonisamide.
The European Medicines Agency (EMA) opened up for consultation product-specific guidance documents on bioequivalence studies for the active substances asenapine, prasugrel, sitagliptin, and zonisamide. The release of the guidance documents follows finalization of bioequivalence guidance on 16 active substances in 2014 and 2015.
The guidance documents, which can be found on EMA’s website, are available for comment until Nov. 1, 2015.
Source: EMA
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
